Work

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

Year: 2018

Type: article

Abstract: Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

Source: Biomedicines

DOI: 10.3390/biomedicines7010001

Authors: Daniel A. Vallera, Robert J. Kreitman

Institutions: University of Minnesota, Masonic Cancer Center, National Institutes of Health, National Cancer Institute

Language: English

Topic: Toxin Mechanisms and Immunotoxins

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,137